Concert Pharmaceuticals (NASDAQ: CNCE) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
Earnings & Valuation
This table compares Concert Pharmaceuticals and Celldex Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Concert Pharmaceuticals||$170,000.00||3,143.60||-$50.72 million||$3.72||6.31|
|Celldex Therapeutics||$6.79 million||58.08||-$128.53 million||($1.01)||-2.87|
Institutional and Insider Ownership
65.4% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.6% of Celldex Therapeutics shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Concert Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Concert Pharmaceuticals and Celldex Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Concert Pharmaceuticals presently has a consensus price target of $24.75, indicating a potential upside of 5.45%. Celldex Therapeutics has a consensus price target of $8.13, indicating a potential upside of 180.17%. Given Celldex Therapeutics’ higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Concert Pharmaceuticals.
This table compares Concert Pharmaceuticals and Celldex Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Concert Pharmaceuticals beats Celldex Therapeutics on 7 of the 13 factors compared between the two stocks.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company’s product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
What are top analysts saying about Concert Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Concert Pharmaceuticals Inc and related companies.